BD Launches Ergonomic Pen Needle Technology to Help Optimize Injection Technique
January 24, 2019 at 06:59 am
Share
BD announced the U.S. Food and Drug Administration 510(k) clearance of its second generation BD Nano™ pen needle, designed for more reliable subcutaneous injection depth. BD Nano™ 2nd gen pen needles offer people who inject diabetes medications a more reliable subcutaneous delivery of their medication, designed to help people better manage their diabetes. Recent updates to the 2019 American Diabetes Association (ADA) Standards of Care highlight the importance of proper injection technique as part of good diabetes management. Proper injection technique is critical to insulin's consistent absorption and there are several factors that can inhibit predictable insulin uptake, including accidental intramuscular injections, which can be caused by greater than required injection force. BD Nano 2nd gen pen needles help mitigate the risks resulting from user injection force variability through its contoured needle base and compensate for variable injection forces by first concentrating, then distributing pressure closely around the injection site (to support more reliable 4 mm target injection depth compared to other 4mm pen needles). The new design has demonstrated more reliable subcutaneous injection depth resulting in up to an 8-fold reduction in calculated intramuscular injection risk. Additionally, the new ergonomic design of BD Nano 2nd gen makes it easier to use, from attachment to disposal, compared to other pen needles, and results in a more comfortable injection experience. This latest advancement to the BD Nano portfolio includes all the benefits its predecessor pen needle has, including BD's 32G x 4 mm pen needle with 5-bevel PentaPoint™ comfort, which has been clinically shown to enter the skin more easily than other 3-bevel needles, providing a smoother and more comfortable injection, and extra thin wall EasyFlow™ technology that increases the medication flow rate, making injections easier. FDA 510(k) clearance will enable BD Nano 2nd gen pen needles to be commercially available in mid-2019.
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows:
- medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.;
- diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.;
- clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc.
Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).